Answers are grounded in this paper and cite their sources.
The new changes in the current European Union legislation regarding the reporting of adverse events for clinical trials complicates pharmacovigilance tasks in non-commercial proposals. The new reporting system implies a greater workload and time commitment for independent researchers who already have fewer economic resources, personnel, and infrastructure.
No takes yet. Share an insight, caveat, or question.
Clara M Rosso Fernández (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: